title: Neopterin: a prognostic variable in operations for lung cancer.
abstract: BACKGROUND
  We studied the prognostic value of preoperatively measured neopterin to predict survival of lung cancer patients. Neopterin is produced and secreted by interferon-gamma-stimulated monocytic cells. High urinary neopterin concentrations are found in patients with viral infections, allograft rejection episodes, and some malignant diseases. In various tumor types high urinary neopterin concentrations are associated with a worse prognosis.
  
  
  METHODS
  Preoperative neopterin levels of 110 patients (29 women, 81 men) with lung cancer including 7 patients with small cell lung cancer were measured and related to the time of survival after operation. Patients with clinically suspected stage IIIB lung cancer were not operated and therefore not enrolled in this study. Infectious diseases were not apparent at the time of preoperative urine sampling. Median postoperative follow-up period was 17.4 months.
  
  
  RESULTS
  In a univariate analysis, patients with a preoperative neopterin concentration of more than 212 micromol/mol creatinine (4th quartile) were determined to have a significantly lower survival probability. In a multivariate analysis, a neopterin concentration of more than 212 micromol/mol creatinine (p < 0.01) and T-stage status (p < 0.005) were determined to be significantly predictive variables for worse survival prognosis.
  
  
  CONCLUSIONS
  Preoperative neopterin proved to be a reliable prognostic factor for survival. Immunology may provide an accurate assessment of tumor aggression and its clinical behavior. In this sense, neopterin can serve as an immunologically based estimation of malignant outgrowth. In patients who are operable by clinical tumor stage but have a high risk for operation, elevated preoperative neopterin may help in the decision for a nonoperative treatment.
authors.affiliation: Department of Thoracic Surgery and Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Austria. rupert.prommegger@uibk.ac.at
authors.forename: R
authors.initials: R
authors.lastname: Prommegger
authors.forename: B
authors.initials: B
authors.lastname: Widner
authors.forename: C
authors.initials: C
authors.lastname: Murr
authors.forename: A
authors.initials: A
authors.lastname: Unger
authors.forename: D
authors.initials: D
authors.lastname: Fuchs
authors.forename: G M
authors.initials: GM
authors.lastname: Salzer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019798:Neopterin / Q000652:urine*; D011013:Pneumonectomy; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate
chemical_list: D019798:Neopterin